Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Recruiting 3 Unknown 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Cyclophosphamide 739 Cisplatin 687 Gemcitabine 641 Bevacizumab 615 Carboplatin 604 Paclitaxel 600 Docetaxel 565 Radiotherapy 536 Fluorouracil 405 Oxaliplatin 387 Rituximab 369 Doxorubicin 360 Capecitabine 342 Filgrastim 333 Etoposide 328 Dexamethasone 312 Irinotecan 309 pembrolizumab 279 Leucovorin 274 Cetuximab 267 Cytarabine 242 Erlotinib Hydrochloride 231 Prednisone 227 Nivolumab 227 Trastuzumab 225 Bortezomib 221 Vincristine 220 Methotrexate 207 Pemetrexed 199 fludarabine phosphate 195

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × pralsetinib × Clear all

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡